On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016

Author: Benzinga Newsdesk | March 11, 2024 09:35am

- SEC Filing

On March 8, 2024, Insmed Incorporated (the "Company") received notice of the exercise by AstraZeneca AB ("AstraZeneca") of its second and final option under the License Agreement, dated October 4, 2016, by and between the Company and AstraZeneca (the "License Agreement"), to further develop and, if approved, commercialize brensocatib in the indications of chronic obstructive pulmonary disease ("COPD") or asthma. The exercise of this second option will permit AstraZeneca to develop brensocatib beyond Phase 2b clinical trials and, if approved, commercialize brensocatib in the indications of COPD or asthma, upon reaching agreement after good faith negotiations resulting in terms, including financial terms, satisfactory to both the Company and AstraZeneca for such further development and commercialization. The Company and AstraZeneca each retain all discretion to determine, among other things, whether any proposed terms are acceptable to such party. The Company retains full development and commercialization rights for brensocatib in all other indications.

Posted In: AZN INSM